| 1 | Combination Hormonal Drug Therapy Inhibits In Vitro Growth of Adult Ovarian Granulosa Tumor Cells. (Summey RM, Iden M, Tsaih SW, Schmidt R, Parashar D, Wang S, Rader JS, Hopp E) Cancer Invest 2026 Mar;44(3):279-295 |
| 2 | Evaluation and management of incomplete ovarian function suppression in premenopausal breast cancer patients receiving anti-hormone therapy. (Patel R, Weil E, Bugamelli S, Carroll E, Steinke K, Stockhausen E, Burfeind J, Mooney C, Retseck J, Sriram D, Deininger J, Halbach A, Sweeney M, Kamaraju S, Chaudhary LN, Cheng YC) Breast Cancer Res 2025 Aug 18;27(1):147 2 Citations |
| 1 | Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast Cancer. (Tau S, Chamberlin MD, Yang H, Marotti JD, Muskus PC, Roberts AM, Carmichael MM, Cressey L, Dragnev CPC, Demidenko E, Hampsch RA, Soucy SM, Kolling FW, Samkoe KS, Alvarez JV, Kettenbach AN, Miller TW) Cancer Res 2025 Mar 14;85(6):1145-1161 10 Citations |
| 3 | The association of distress and depression screening measures and other electronic health record information with adjuvant endocrine therapy persistence. (Neuner JM, Stolley M, Kamaraju S, Tiegs J, Sparapani R, Makris V, Flynn KE) Breast Cancer Res Treat 2025 Feb;209(3):541-552 |
| 3 | Integrated single-cell analysis reveals distinct epigenetic-regulated cancer cell states and a heterogeneity-guided core signature in tamoxifen-resistant breast cancer. (Fang K, Ohihoin AG, Liu T, Choppavarapu L, Nosirov B, Wang Q, Yu XZ, Kamaraju S, Leone G, Jin VX) Genome Med 2024 Nov 18;16(1):134 18 Citations |
| 3 | Adherence to adjuvant endocrine therapy for breast cancer: a qualitative exploration of attribution of symptoms among post-menopausal women. (Lee AY, Lyons AT, Makris V, Kamaraju S, Stolley MR, Neuner JM, Flynn KE) Support Care Cancer 2024 Apr 02;32(4):265 1 Citation |
| 1 | Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer. (Schwartz GN, Kaufman PA, Giridhar KV, Marotti JD, Chamberlin MD, Arrick BA, Makari-Judson G, Goetz MP, Soucy SM, Kolling F, Demidenko E, Miller TW) Clin Cancer Res 2023 Aug 01;29(15):2767-2773 6 Citations |
| 2 | Prognostic Outcomes of Signet Ring Cell Carcinoma of the Breast. (Mehdi M, Kong AL, Frebault J, Huang S, Huang CC, Cortina CS) J Surg Res 2021 Aug;264:138-148 11 Citations |
| 1 | A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. (Duska LR, Filiaci VL, Walker JL, Holman LL, Hill EK, Moore RG, Ring KL, Pearl ML, Muller CY, Kushnir CL, Lankes HA, Samuelson MI, Carrick KS, Rajan A, Rodgers WH, Kohn EC, Piekarz R, Leslie KK) Clin Cancer Res 2021 May 15;27(10):2734-2741 18 Citations |
| 1 | Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant. (Schwartz G, Shee K, Romo B, Marotti J, Kisselev A, Lewis L, Miller T) Oncologist 2021 Jun;26(6):467-e924 8 Citations |
| 3 | The 3D genomic landscape of differential response to EGFR/HER2 inhibition in endocrine-resistant breast cancer cells. (Yang Y, Choppavarapu L, Fang K, Naeini AS, Nosirov B, Li J, Yang K, He Z, Zhou Y, Schiff R, Li R, Hu Y, Wang J, Jin VX) Biochim Biophys Acta Gene Regul Mech 2020 Nov;1863(11):194631 13 Citations |
| 1 | Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance. (Bi M, Zhang Z, Jiang YZ, Xue P, Wang H, Lai Z, Fu X, De Angelis C, Gong Y, Gao Z, Ruan J, Jin VX, Marangoni E, Montaudon E, Glass CK, Li W, Huang TH, Shao ZM, Schiff R, Chen L, Liu Z) Nat Cell Biol 2020 Jun;22(6):701-715 110 Citations |
| 4 | Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. (Pidala J, Hamadani M, Dawson P, Martens M, Alousi AM, Jagasia M, Efebera YA, Chhabra S, Pusic I, Holtan SG, Ferrara JLM, Levine JE, Mielcarek M, Anasetti C, Antin JH, Bolaños-Meade J, Howard A, Logan BR, Leifer ES, Pritchard TS, Horowitz MM, MacMillan ML) Blood 2020 Jan 09;135(2):97-107 77 Citations |
| 1 | In vivo longitudinal imaging of RNA interference-induced endocrine therapy resistance in breast cancer. (Biswal NC, Fu X, Jagtap JM, Shea MJ, Kumar V, Lords T, Roy R, Schiff R, Joshi A) J Biophotonics 2020 Jan;13(1):e201900180 1 Citation |
| 5 | The association of pharmacy fill synchronization with breast cancer endocrine therapy adherence. (Neuner JM, Fergestrom NM, Laud PW, Nattinger AB, Beyer KMM, Flynn KE, Pezzin LE) Cancer 2019 Nov 15;125(22):3960-3965 6 Citations |
| 1 | Surgery in the Older Patient with Breast Cancer. (Frebault J, Bergom C, Kong AL) Curr Oncol Rep 2019 Jun 25;21(8):69 4 Citations |
| 2 | Factors Influencing Prescription Drug Synchronization: The Complex Role of Number of Medications. (Neuner JM, Fergestrom N, Laud PW, Pezzin L) J Manag Care Spec Pharm 2019 Jun;25(6):714-718 4 Citations |
| 1 | Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistance. (Zhou Y, Gerrard DL, Wang J, Li T, Yang Y, Fritz AJ, Rajendran M, Fu X, Stein G, Schiff R, Lin S, Frietze S, Jin VX) Nat Commun 2019 Apr 03;10(1):1522 63 Citations |
| 1 | Nipple changes in an 85-year-old man. (Cortina CS, Madrigrano A) CMAJ 2019 Feb 04;191(5):E135 2 Citations |
| 3 | Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study. (Kamaraju S, Shi Y, Smith E, Nattinger AB, Laud P, Neuner J) Clin Cardiol 2019 Jan;42(1):93-100 31 Citations |
| 1 | Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer. (Rosati R, Polin L, Ducker C, Li J, Bao X, Selvakumar D, Kim S, Xhabija B, Larsen M, McFall T, Huang Y, Kidder BL, Fribley A, Saxton J, Kakuta H, Shaw P, Ratnam M) Clin Cancer Res 2018 Dec 15;24(24):6509-6522 16 Citations |
| 1 | Are Providers and Patients Following Hormonal Therapy Guidelines for Patients Over the Age of 70? The Influence of CALGB 9343. (Cortina CS, Agarwal S, Mulder LL, Poirier J, Rao R, Ansell DA, Madrigrano A) Clin Breast Cancer 2018 Dec;18(6):e1289-e1292 10 Citations |
| 4 | Fractures in a nationwide population-based cohort of users of breast cancer hormonal therapy. (Neuner JM, Shi Y, Kong AL, Kamaraju S, Smith EC, Smallwood AJ, Laud PW, Charlson JA) J Cancer Surviv 2018 Apr;12(2):268-275 10 Citations |
| 4 | Geographic Variation of Adjuvant Breast Cancer Therapy Initiation in the United States: Lessons From Medicare Part D. (Charlson JA, McGinley EL, Nattinger AB, Neuner JM, Pezzin LE) J Natl Compr Canc Netw 2017 Dec;15(12):1509-1517 4 Citations |
| 3 | Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy. (Biggers A, Shi Y, Charlson J, Smith EC, Smallwood AJ, Nattinger AB, Laud PW, Neuner JM) J Clin Oncol 2016 Dec 20;34(36):4398-4404 39 Citations |
| 1 | The use of concurrent hormonotherapy and radiotherapy does not deteriorate radiation-induced cardiac toxicity. (Yavas C, Yavas G, Toy H, Ata O) Hum Exp Toxicol 2017 Aug;36(8):795-801 2 Citations |
| 1 | Racial differences in receipt of adjuvant hormonal therapy among Medicaid enrollees in South Carolina diagnosed with breast cancer. (Felder TM, Do DP, Lu ZK, Lal LS, Heiney SP, Bennett CL) Breast Cancer Res Treat 2016 May;157(1):193-200 5 Citations |
| 1 | Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group. (Postlewait LM, Ethun CG, Tran TB, Prescott JD, Pawlik TM, Wang TS, Glenn J, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick JK, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA, Staley CA, Poultsides GA, Maithel SK) J Am Coll Surg 2016 Apr;222(4):480-90 77 Citations |
| 1 | Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08. (Voog JC, Paulus R, Shipley WU, Smith MR, McGowan DG, Jones CU, Bahary JP, Zeitzer KL, Souhami L, Leibenhaut MH, Rotman M, Husain SM, Gore E, Raben A, Chafe S, Sandler HM, Efstathiou JA) Eur Urol 2016 Feb;69(2):204-10 41 Citations |
| 1 | A Qualitative Study Exploring the Perceptions of Sedentary Behavior in Prostate Cancer Survivors Receiving Androgen-Deprivation Therapy. (Trinh L, Arbour-Nicitopoulos KP, Sabiston CM, Alibhai SM, Jones JM, Berry SR, Loblaw A, Faulkner GE) Oncol Nurs Forum 2015 Jul;42(4):398-406 20 Citations |
| 1 | Expression of estrogen and progesterone receptors across human malignancies: new therapeutic opportunities. (Munoz J, Wheler J, Kurzrock R) Cancer Metastasis Rev 2015 Dec;34(4):547-61 14 Citations |
| 1 | Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. (Pisansky TM, Hunt D, Gomella LG, Amin MB, Balogh AG, Chinn DM, Seider MJ, Duclos M, Rosenthal SA, Bauman GS, Gore EM, Rotman MZ, Lukka HR, Shipley WU, Dignam JJ, Sandler HM) J Clin Oncol 2015 Feb 01;33(4):332-9 120 Citations |
| 1 | Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. (Fu X, Creighton CJ, Biswal NC, Kumar V, Shea M, Herrera S, Contreras A, Gutierrez C, Wang T, Nanda S, Giuliano M, Morrison G, Nardone A, Karlin KL, Westbrook TF, Heiser LM, Anur P, Spellman P, Guichard SM, Smith PD, Davies BR, Klinowska T, Lee AV, Mills GB, Rimawi MF, Hilsenbeck SG, Gray JW, Joshi A, Osborne CK, Schiff R) Breast Cancer Res 2014 Sep 11;16(5):430 72 Citations |
| 2 | RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients. (Kachnic LA, Pugh SL, Tai P, Smith M, Gore E, Shah AB, Martin AG, Kim HE, Nabid A, Lawton CA) Prostate Cancer Prostatic Dis 2013 Dec;16(4):382-6 32 Citations |
| 1 | Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer. (Hsu PY, Hsu HK, Lan X, Juan L, Yan PS, Labanowska J, Heerema N, Hsiao TH, Chiu YC, Chen Y, Liu Y, Li L, Li R, Thompson IM, Nephew KP, Sharp ZD, Kirma NB, Jin VX, Huang TH) Cancer Cell 2013 Aug 12;24(2):197-212 46 Citations |
| 1 | Endocrine resistance: what do we know? (Miller TW) Am Soc Clin Oncol Educ Book 2013 19 Citations |
| 1 | A hidden Markov model to identify combinatorial epigenetic regulation patterns for estrogen receptor α target genes. (Bonneville R, Jin VX) Bioinformatics 2013 Jan 01;29(1):22-8 9 Citations |
| 1 | Comparison of the effects of aromatase inhibitors and tamoxifen on radiation-induced lung toxicity: results of an experimental study. (Yavas G, Yavas C, Acar H, Toy H, Yuce D, Ata O) Support Care Cancer 2013 Mar;21(3):811-7 20 Citations |
| 1 | Body composition changes in females treated for breast cancer: a review of the evidence. (Sheean PM, Hoskins K, Stolley M) Breast Cancer Res Treat 2012 Oct;135(3):663-80 90 Citations |
| 1 | Medical therapy of endometrial cancer: current status and promising novel treatments. (Hill EK, Dizon DS) Drugs 2012 Mar 26;72(5):705-13 40 Citations |
| 3 | p38γ mitogen-activated protein kinase (MAPK) confers breast cancer hormone sensitivity by switching estrogen receptor (ER) signaling from classical to nonclassical pathway via stimulating ER phosphorylation and c-Jun transcription. (Qi X, Zhi H, Lepp A, Wang P, Huang J, Basir Z, Chitambar CR, Myers CR, Chen G) J Biol Chem 2012 Apr 27;287(18):14681-91 27 Citations |
| 1 | A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. (Fox EM, Miller TW, Balko JM, Kuba MG, Sánchez V, Smith RA, Liu S, González-Angulo AM, Mills GB, Ye F, Shyr Y, Manning HC, Buck E, Arteaga CL) Cancer Res 2011 Nov 01;71(21):6773-84 140 Citations |
| 1 | A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. (Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, González-Angulo AM, Mills GB, Miller WR, Wu H, Shyr Y, Arteaga CL) Clin Cancer Res 2011 Apr 01;17(7):2024-34 90 Citations |
| 4 | Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients. (Neuner JM, Yen TW, Sparapani RA, Laud PW, Nattinger AB) Osteoporos Int 2011 Nov;22(11):2847-55 33 Citations |
| 1 | Multiple congenital red-brown macules, thrombocytopenia, and gastrointestinal bleeding. Diagnosis: Multifocal lymphangioendotheliomatosis with thrombocytopenia (MLT). (Campbell CM, Beckum KM, Hammers YA, North PE, Drolet BA, Theos A) Pediatr Dermatol 2010;27(4):395-6 5 Citations |
| 2 | The economic consequences of breast cancer adjuvant hormonal treatments. (Pezzin LE, O'Niel MB, Nattinger AB) J Gen Intern Med 2009 Nov;24 Suppl 2(Suppl 2):S446-50 26 Citations |
| 2 | Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. (Grubbs EG, Callender GG, Xing Y, Perrier ND, Evans DB, Phan AT, Lee JE) Ann Surg Oncol 2010 Jan;17(1):263-70 147 Citations |
| 1 | Novel flufenamic acid analogues as inhibitors of androgen receptor mediated transcription. (Féau C, Arnold LA, Kosinski A, Zhu F, Connelly M, Guy RK) ACS Chem Biol 2009 Oct 16;4(10):834-43 24 Citations |
| 1 | The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia. (Pottier N, Yang W, Assem M, Panetta JC, Pei D, Paugh SW, Cheng C, Den Boer ML, Relling MV, Pieters R, Evans WE, Cheok MH) J Natl Cancer Inst 2008 Dec 17;100(24):1792-803 58 Citations |
| 1 | Management of complications of androgen deprivation therapy in the older man. (Mohile SG, Mustian K, Bylow K, Hall W, Dale W) Crit Rev Oncol Hematol 2009 Jun;70(3):235-55 71 Citations |
| 1 | Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. (Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, Yun J, Zhao H, Mascarenhas J, Wyatt D, Antico G, Hao L, Yao K, Rajan P, Hicks C, Siziopikou K, Selvaggi S, Bashir A, Bhandari D, Marchese A, Lendahl U, Qin JZ, Tonetti DA, Albain K, Nickoloff BJ, Miele L) Cancer Res 2008 Jul 01;68(13):5226-35 314 Citations |
| 1 | Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma. (Attia S, Holen KD, Thomas JP, Richie K, Dzelak T, Teeter K, Warren D, Bilger A, Fine J, Eickhoff J, Drinkwater N, Mulkerin D, Morgan-Meadows S) Clin Adv Hematol Oncol 2008 Jan;6(1):44-54 5 Citations |
| 2 | Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma. (Gonzalez RJ, Tamm EP, Ng C, Phan AT, Vassilopoulou-Sellin R, Perrier ND, Evans DB, Lee JE) Surgery 2007 Dec;142(6):867-75; discussion 867-75 79 Citations |
| 1 | Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review. (Bylow K, Mohile SG, Stadler WM, Dale W) Cancer 2007 Dec 15;110(12):2604-13 112 Citations |
| 1 | Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer. (Fleshner N, Keane TE, Lawton CA, Mulders PF, Payne H, Taneja SS, Morris T) Prostate Cancer Prostatic Dis 2008;11(1):46-52 8 Citations |
| 1 | Impact of randomized clinical trial results in the national comprehensive cancer network on the use of tamoxifen after breast surgery for ductal carcinoma in situ. (Yen TW, Kuerer HM, Ottesen RA, Rouse L, Niland JC, Edge SB, Theriault RL, Weeks JC) J Clin Oncol 2007 Aug 01;25(22):3251-8 47 Citations |
| 1 | A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. (Mohile SG, Bylow K, Dale W, Dignam J, Martin K, Petrylak DP, Stadler WM, Rodin M) Cancer 2007 Feb 15;109(4):802-10 232 Citations |
| 1 | The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup. (McLeod DG, See WA, Klimberg I, Gleason D, Chodak G, Montie J, Bernstein G, Morris C, Armstrong J) J Urol 2006 Jul;176(1):75-80 41 Citations |
| 1 | Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021. (Robins HI, Won M, Seiferheld WF, Schultz CJ, Choucair AK, Brachman DG, Demas WF, Mehta MP) Neuro Oncol 2006 Jan;8(1):47-52 60 Citations |
| 1 | Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10. (Shipley WU, Desilvio M, Pilepich MV, Roach M 3rd, Wolkov HB, Sause WT, Rubin P, Lawton CA) Int J Radiat Oncol Biol Phys 2006 Mar 15;64(4):1162-7 48 Citations |
| 1 | Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. (Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D) Int J Radiat Oncol Biol Phys 2005 Apr 01;61(5):1285-90 855 Citations |
| 1 | Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. (Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach M 3rd, Shipley WU, Hanks GE, Sandler HM) J Clin Oncol 2004 Jun 01;22(11):2133-40 145 Citations |
| 1 | Antiangiogenic treatment of mesenteric desmoid tumors with toremifene and interferon alfa-2b: report of two cases. (Heidemann J, Ogawa H, Otterson MF, Shidham VB, Binion DG) Dis Colon Rectum 2004 Jan;47(1):118-22 28 Citations |
| 1 | Adjuvant hormone therapy after radiation or surgery for localized or locally advanced prostate cancer. (See WA) Curr Treat Options Oncol 2003 Oct;4(5):351-62 6 Citations |
| 1 | Hormones and radiation therapy in locally advanced adenocarcinoma of the prostate. (Lawton CA) Semin Radiat Oncol 2003 Apr;13(2):141-51 9 Citations |
| 1 | Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10. (Shipley WU, Lu JD, Pilepich MV, Heydon K, Roach M, Wolkov HB, Sause WT, Rubin P, Lawton CA, Machtay M) Int J Radiat Oncol Biol Phys 2002 Dec 01;54(5):1302-10 61 Citations |
| 1 | Octreotide in pediatric patients. (Heikenen JB, Pohl JF, Werlin SL, Bucuvalas JC) J Pediatr Gastroenterol Nutr 2002 Nov;35(5):600-9 53 Citations |
| 1 | Retrospective assessment of hypercoagulability in breast cancer prevention trial. (Abramson N, Aster RH) J Clin Oncol 2002 Oct 01;20(19):4133-4 4 Citations |
| 1 | Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. (Horwitz EM, Winter K, Hanks GE, Lawton CA, Russell AH, Machtay M) Int J Radiat Oncol Biol Phys 2001 Mar 15;49(4):947-56 103 Citations |
| 1 | Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. (Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, Coughlin CT, Pilepich MV) Int J Radiat Oncol Biol Phys 2001 Mar 15;49(4):937-46 374 Citations |
| 1 | Carcinoid crisis during transesophageal echocardiography. (Janssen M, Salm EF, Breburda CS, van Woerkens LJ, de Herder WW, v/d Zwaan C, Roelandt JR) Intensive Care Med 2000 Feb;26(2):254 26 Citations |
| 1 | Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. (Rowlings PA, Williams SF, Antman KH, Fields KK, Fay JW, Reed E, Pelz CJ, Klein JP, Sobocinski KA, Kennedy MJ, Freytes CO, McCarthy PL Jr, Herzig RH, Stadtmauer EA, Lazarus HM, Pecora AL, Bitran JD, Wolff SN, Gale RP, Armitage JO, Vaughan WP, Spitzer G, Horowitz MM) JAMA 1999 Oct 13;282(14):1335-43 68 Citations |
| 1 | Cell cycle regulation of human pancreatic cancer by tamoxifen. (Robinson EK, Grau AM, Evans DB, Smid CM, Chiao PJ, Abbruzzese JL, Grimm EA) Ann Surg Oncol 1998 Jun;5(4):342-9 20 Citations |
| 1 | Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. (Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU, Grignon D) J Clin Oncol 1997 Mar;15(3):1013-21 583 Citations |
| 1 | p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. (Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MV, Forman JD, Mesic J, Fu KK, Abrams RA, Pajak TF, Shipley WU, Cox JD) J Natl Cancer Inst 1997 Jan 15;89(2):158-65 164 Citations |
| 1 | A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer. (Dreicer R, Kemp JD, Stegink LD, Cardillo T, Davis CS, Forest PK, See WA) Cancer Invest 1997;15(4):311-7 22 Citations |
| 1 | Treatment of submucous fibroids, and outcome of assisted conception. (Narayan R, Rajat, Goswamy K) J Am Assoc Gynecol Laparosc 1994 Aug;1(4 Pt 1):307-11 84 Citations |
